Increasing the Interval of Canakinumab Administration Effectively Supports the Remission of Schnitzler’s Syndrome

Increasing the Interval of Canakinumab Administration Effectively Supports the Remission of Schnitzler’s Syndrome

Schnitzler’s syndrome (SchS) is a rare, disabling, autoinflammatory disorder characterized by recurrent urticarial rash and monoclonal IgM gammopathy. Interleukin-1 beta (IL-1β) plays an important role in the pathophysiology of SchS. Only anecdotal reports demonstrate the efficiency and safety of hu...

Full description

Bibliographic Details
Main Authors: Vadim R. Gorodetskiy, Svetlana O. Salugina, Evgeny S. Fedorov
Format: Article
Language:English
Published: Hindawi Limited 2018-01-01
Series:Case Reports in Rheumatology
Online Access:http://dx.doi.org/10.1155/2018/5416907
id doaj-61d71f36b1804e11817a163fbf61ec19
record_format Article
spelling doaj-61d71f36b1804e11817a163fbf61ec192020-11-25T00:44:13ZengHindawi LimitedCase Reports in Rheumatology2090-68892090-68972018-01-01201810.1155/2018/54169075416907Increasing the Interval of Canakinumab Administration Effectively Supports the Remission of Schnitzler’s SyndromeVadim R. Gorodetskiy0Svetlana O. Salugina1Evgeny S. Fedorov2V.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Kashirskoye Shosse 34A, Moscow 115522, RussiaV.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Kashirskoye Shosse 34A, Moscow 115522, RussiaV.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Kashirskoye Shosse 34A, Moscow 115522, RussiaSchnitzler’s syndrome (SchS) is a rare, disabling, autoinflammatory disorder characterized by recurrent urticarial rash and monoclonal IgM gammopathy. Interleukin-1 beta (IL-1β) plays an important role in the pathophysiology of SchS. Only anecdotal reports demonstrate the efficiency and safety of human monoclonal anti-human IL-1β antibody (canakinumab) use in SchS therapy. However, there are no generally accepted recommendations concerning the scheme (or frequency) of canakinumab use for this disease. Here, we report the effective long-term treatment of SchS in a 44-year-old male with a standard canakinumab dose (150 mg) but with an increased 4-month injection interval.http://dx.doi.org/10.1155/2018/5416907
collection DOAJ
language English
format Article
sources DOAJ
author Vadim R. Gorodetskiy
Svetlana O. Salugina
Evgeny S. Fedorov
spellingShingle Vadim R. Gorodetskiy
Svetlana O. Salugina
Evgeny S. Fedorov
Increasing the Interval of Canakinumab Administration Effectively Supports the Remission of Schnitzler’s Syndrome
Case Reports in Rheumatology
author_facet Vadim R. Gorodetskiy
Svetlana O. Salugina
Evgeny S. Fedorov
author_sort Vadim R. Gorodetskiy
title Increasing the Interval of Canakinumab Administration Effectively Supports the Remission of Schnitzler’s Syndrome
title_short Increasing the Interval of Canakinumab Administration Effectively Supports the Remission of Schnitzler’s Syndrome
title_full Increasing the Interval of Canakinumab Administration Effectively Supports the Remission of Schnitzler’s Syndrome
title_fullStr Increasing the Interval of Canakinumab Administration Effectively Supports the Remission of Schnitzler’s Syndrome
title_full_unstemmed Increasing the Interval of Canakinumab Administration Effectively Supports the Remission of Schnitzler’s Syndrome
title_sort increasing the interval of canakinumab administration effectively supports the remission of schnitzler’s syndrome
publisher Hindawi Limited
series Case Reports in Rheumatology
issn 2090-6889
2090-6897
publishDate 2018-01-01
description Schnitzler’s syndrome (SchS) is a rare, disabling, autoinflammatory disorder characterized by recurrent urticarial rash and monoclonal IgM gammopathy. Interleukin-1 beta (IL-1β) plays an important role in the pathophysiology of SchS. Only anecdotal reports demonstrate the efficiency and safety of human monoclonal anti-human IL-1β antibody (canakinumab) use in SchS therapy. However, there are no generally accepted recommendations concerning the scheme (or frequency) of canakinumab use for this disease. Here, we report the effective long-term treatment of SchS in a 44-year-old male with a standard canakinumab dose (150 mg) but with an increased 4-month injection interval.
url http://dx.doi.org/10.1155/2018/5416907
work_keys_str_mv AT vadimrgorodetskiy increasingtheintervalofcanakinumabadministrationeffectivelysupportstheremissionofschnitzlerssyndrome
AT svetlanaosalugina increasingtheintervalofcanakinumabadministrationeffectivelysupportstheremissionofschnitzlerssyndrome
AT evgenysfedorov increasingtheintervalofcanakinumabadministrationeffectivelysupportstheremissionofschnitzlerssyndrome
_version_ 1725275631507210240

Similar Items